PAID ADVERTISMENT

Discover innovative cardiovascular products

Spend your lunchtime at the Cardiovascular Expert Theaters, located in the Science & Technology Hall. These sessions, which are not part of the official programming, are presented by industry supporters featuring their newest cardiovascular products. AHA will provide a complimentary lunch.

Sunday, Nov. 12, 11:15 a.m.-Noon
Booth 1473
Supported by Amgen
Clinical Inertia and LDL-C Levels in Atherosclerosis

Booth 2467
Supported by Sanofi – Regeneron
PRALUENT® (alirocumab) Injection: The Time to Treat the Appropriate Patient is Now

Booth 2701
Supported by Janssen Pharmaceuticals, Inc.
Clinical Data and Real-World Evidence to Support NVAF & DVT/PE Treatment Decision-Making

Sunday, Nov. 12, 12:30-1:15 p.m.
Booth 1473
Supported by Boehringer Ingelheim
JARDIANCE® (empagliflozin) tablets: Evolving Clinical Development

Booth 2467
Supported by Amgen
Repatha (evolocumab): Take the Next Step

Booth 2701
Supported by Novartis
Optimization of Care for Chronic Heart Failure in the Hospitalized Patient

Sunday, Nov. 12, 3-3:45 p.m.
Booth 2701
Supported by Novartis
Vascular Inflammation in Atherosclerosis: Clinical Implications

Monday, Nov. 13, Noon-12:45 p.m.
Booth 1473
Supported by Janssen Pharmaceuticals, Inc.
The Underlying Thrombotic Risk in Patients With Atherosclerotic Vascular Disease

Booth 2701
Supported by Aralez
Persistent Vascular Risk: Reducing Thrombotic CV Events in the Management of Patients With Systemic Atherothrombosis

Monday, Nov. 13, 1:15-2 p.m.
Booth 1473
Supported by Amgen
The Repatha Patient Journey

Booth 2467
Supported by Novartis
Optimizing Treatment to Improve Outcomes: Implementing the New Guideline for Managing Heart Failure With Reduced Ejection Fraction

Booth 2701
Supported by Boehringer Ingelheim
A Closer Look at New, Real-World Evidence for an OAC with Reversal

Monday, Nov. 13, 3:15-4 p.m.
Booth 2701
Supported by Janssen Pharmaceuticals, Inc.
Awaken a Transformation in Type 2 Diabetes Management

Tuesday, Nov. 14, Noon-12:45 p.m.
Booth 1473
Supported by Amgen
Cardiovascular Disease: From Risk Factors to Clinical Discussions

Booth 2467
Supported by Novo Nordisk
Advancements in the Management of Patients With Type 2 Diabetes: Results From a Large Cardiovascular Outcomes Trial

Top